Corindus Vascular Robotics Inc (A:CVRS)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
See Regulatory Filings on SEC
Company Contact
Address: 309 Waverley Oaks Rd Ste 105
WALTHAM MA 02452-8451
Tel: 1-508-6533335
IR: See website
Key People
Business Overview
Corindus Vascular Robotics, Inc. is engaged in robotic-assisted vascular interventions. The Company's CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System it brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. It operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit.
Financial Overview
For the fiscal year ended 31 December 2018, Corindus Vascular Robotics Inc revenues increased 12% to $10.8M. Net loss applicable to common stockholders increased 25% to $42.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Selling, general and administrative - Ba increase of 11% to $24.5M (expense), Interest,net increase from $214K to $884K (expense).
Employees: 90 as of Mar 8, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $390.42M as of Dec 31, 2018
Annual revenue (TTM): $10.78M as of Dec 31, 2018
EBITDA (TTM): -$33.11M as of Dec 31, 2018
Net annual income (TTM): -$42.64M as of Dec 31, 2018
Free cash flow (TTM): -$32.77M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 206,212,607 as of Mar 12, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization